India, July 27 -- Shares of Epigral Limited are likely to remain in focus after the company reported healthy growth in its Q1 FY27 earnings, driven by higher sales volumes, improved product realizations and resilient demand despite global macroeconomic volatility. Alongside its quarterly performance, the company announced fresh investments in specialty chemicals and continued execution of multiple capacity expansion projects aimed at strengthening its integrated manufacturing platform.

Epigral Limited has a total market capitalization of approximately Rs. 5,025.97 crore. The company's shares were trading at Rs. 1165 apiece on the stock exchange. The stock has gained 7.55 percent over the last five trading sessions and gained 5.33 percent...